Leading Solutions for Spatial Multi-Omics Analysis
Bridging Spatial Transcriptomics, Proteomics, and Metabolomics
Modern biological research has evolved beyond bulk analysis. While traditional transcriptomics provides a comprehensive list of active genes in a sample, it completely lacks spatial context. Cells do not operate in isolation; their behavior is heavily dictated by their microenvironment. Spatial Transcriptomics (ST) has emerged as a revolutionary technology, enabling researchers to map gene expression directly onto the histological landscape of tissue sections. However, to truly understand cellular function, we must look beyond transcription. Proteins are the primary functional agents of the cell, and metabolites represent the ultimate physiological output. Integrating Spatial Transcriptomics with proteomics and metabolomics offers an unprecedented, multidimensional view of biological systems.
By correlating spatial gene expression with localized protein abundance and metabolic profiles, researchers can decode the complex molecular networks driving health and disease. This multi-omics paradigm shift allows us to validate transcriptional activity with functional protein translation and metabolic phenotypes. BMKGene is at the forefront of this revolution, providing advanced sequencing, bioinformatics, and proprietary technologies like the BMKMANU S3000 spatial transcriptome platform to seamlessly bridge these distinct molecular layers.
Industrial and Commercial Landscape of Spatial Multi-Omics
The global spatial biology market is experiencing exponential growth, projected to surpass billions of dollars by 2030. This expansion is fueled by the biopharmaceutical industry’s demand for precise biomarkers, target discovery, and patient stratification tools in clinical trials. Traditional drug discovery pipelines suffer from high failure rates due to a lack of efficacy or unexpected toxicity. Spatial multi-omics mitigates these risks by revealing exactly how drugs interact with target cells within their native tissue microenvironments.
In the industrial sector, spatial transcriptomics, combined with proteomics and metabolomics, is revolutionizing oncology, immunology, and neurology. Pharmaceutical giants are actively partnering with genomics service providers to map tumor-immune cell interactions, discover novel spatial biomarkers for immunotherapies, and trace metabolic reprogramming in diseased organs. As the technology matures, standardizing workflows and lowering costs through automated platforms like BMKGene’s Brilliant Lab 1000 are crucial to transitioning these workflows from academic research to high-throughput clinical diagnostics.
Why the Industry is Pivoting to Spatial Integration:
- High-Resolution Biomarker Discovery: Identifying spatial co-localization of drug targets and effector cells.
- Optimized Clinical Trials: Stratifying patients based on spatial tissue profiles to predict treatment response.
- Deep Mechanistic Insight: Unraveling the metabolic pathways and signaling networks underlying therapy resistance.
- Reduced Development Timelines: Accelerating lead optimization by visualizing drug distribution and cellular response simultaneously.
Deep-Dive Application Scenarios
1. Tumor Microenvironment (TME) & Immunotherapy
In cancer immunotherapy, the spatial distribution of immune cells relative to tumor cells determines therapeutic success. Combining spatial transcriptomics with spatial proteomics allows researchers to map immune checkpoint expression (like PD-1/PD-L1) and cytotoxic T-cell infiltration. Concurrently, spatial metabolomics highlights areas of hypoxia and lactate accumulation, which suppress immune responses, providing a complete blueprint for next-generation drug design.
2. Neurodegenerative Diseases
Diseases like Alzheimer’s and Parkinson’s are characterized by localized pathology, such as amyloid-beta plaques and alpha-synuclein aggregates. Spatial transcriptomics reveals the transcriptional changes in microglia and astrocytes surrounding these plaques. Integrating this with proteomics identifies translated synaptic proteins, while metabolomics tracks localized oxidative stress and energy metabolism failures in specific brain regions.
3. Crop Science & Plant Biology
Beyond human health, spatial multi-omics is transforming agriculture. Researchers use spatial transcriptomics to map gene expression in plant tissues under environmental stress (e.g., drought or salinity). Combining this with spatial metabolomics allows for the visualization of stress-responsive metabolites (like flavonoids or proline) in specific cell layers, driving the development of climate-resilient crops.
Biomarker Technologies (BMKGene)
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
Our Advanced Platforms & Infrastructure
Multi-level Sequencing Platforms
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5, MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7
Bionano Irys system
Waters XEVO G2-XS QTOF
QTRAP 6500+
Advanced Molecular Laboratory
Spanning over 20,000 square feet, our facility houses advanced biomolecular laboratory instruments. Standardized labs for sample extraction, library construction, clean rooms, and sequencing operate under strict SOPs, ensuring the highest standards of data quality and reproducibility.
BMKCloud Bioinformatic Platform
Our self-developed BMKCloud platform features CPUs with 41,104 memory, 3 PB of total storage, and 4,260 computing cores, delivering a peak computing power over 121,708.8 Gflop per second. It provides a reliable, easy-to-use online bioinformatics analysis ecosystem for global researchers.
Fully Automated NGS & Multi-Omics Production Line
Brilliant Lab 1000 (BL1000)
Biomarker Technologies (BMKGene) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to the high-throughput NGS library construction service.
BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
State-of-the-Art Production Facility
Enterprise Qualifications & Patents
Our commitment to quality, research, and innovation is validated by numerous global certifications, patents, and joint laboratory collaborations.
Proprietary Patents & Software Copyrights
Connect with Our Spatial Multi-Omics Experts
For inquiries about our spatial transcriptomics, proteomics, metabolomics products, or customized project pricelists, please leave your email. We will get in touch with you within 24 hours.
Inquiry NowExplore All Services & Solutions
